- Pharmacia & Upjohn has launched its new Nicorette Inhaler product for smoking cessation in Denmark, its first market. This is the first inhaled nicotine replacement product to be introduced anywhere in the world, and the Danish launch is the first of a series planned in Europe and elsewhere. P&U hopes the over-the-counter product will address some of the behavioral aspects of cigarette dependence. P&U says that its market research has found that up to 50% of smokers surveyed expressed an interest in trialling the product. Since its explosive growth and peak in the early 1990s, the nicotine replacement market has now stabilized at around $500 million a year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze